Post a brief explanation of the psychological disorder presented (two to three sentences) and the decision steps you applied in completing the interactive media piece for the psychological disorder you selected
This week we will review Pharmacology for Psychological Disorders and participate in a discussion forum.
For this Discussion, you will select ONE interactive media piece to practice decision making when treating patients with psychological disorders.
Here is the link to the interactive media i choose
http://cdnfiles.laureate.net/2dett4d/Walden/NURS/6521/05/mm/decision_trees/week_05/index.html
You will recommend the most effective pharmacotherapeutic to treat the psychological disorder presented and examine potential impacts of pharmacotherapeutics on a patient’s pathophysiology.
Post a brief explanation of the psychological disorder presented (two to three sentences) and the decision steps you applied in completing the interactive media piece for the psychological disorder you selected. What did you select for step 1, 2 and 3?
Then, explain how the administration of the associated pharmacotherapeutics (drugs) you recommended may impact the patient’s pathophysiology. What are the mechanism of action, therapeutic effects and side effects of the drugs you selected for steps 1, 2 and 3.
How might these potential impacts inform how you would suggest treatment plans for this patient? Be specific and provide examples.
To get your thought process going, consider the following…What symptoms are seen in the patient? Will the drug you chose affect the symptoms? Why did you choose this drug? Why did you exclude the other options for this patient?
REQUIRED READING:
Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.) St. Louis, MO: Elsevier.
- Chapter 26, “Antipsychotic Agents and Their Use in Schizophrenia” (pp. 203–213)
- Chapter 27, “Antidepressants” (pp. 214–226)
- Chapter 28, “Drugs for Bipolar Disorder” (pp. 228–233)
- Chapter 29, “Sedative-Hypnotic Drugs” (pp. 234–242)
- Chapter 30, “Management of Anxiety Disorders” (pp. 243–247)
- Chapter 31, “Central Nervous System Stimulants and Attention-Deficit/Hyperactivity Disorder” (pp. 248–254)